PubMed, Embase, and Cochrane databases were retrieved until August 2022. Randomized trials and non-randomized controlled studies evaluating ceftolozane-tazobactam and its comparators in adult patients with GNB infections were included.
A total of 13 studies were included. Overall, patients receiving ceftolozane-tazobactam had significant advantages in clinical cure (odds ratio [OR], 1.62; 95% CI, 1.05-2.51) and microbiological eradication (OR, 1.43; 95% CI, 1.19-1.71), especially in Pseudomonas aeruginosa-infected patients. Ceftolozane-tazobactam had a significant advantage in clinical success or microbial eradication compared with polymyxin/aminoglycosides (PL/AG) or levofloxacin. There were no significant differences in adverse events (AEs), Clostridium difficile infection (CDI), and mortality between ceftolozane-tazobactam and comparators. Notably, ceftolozane-tazobactam showed a significantly lower risk of acute kidney injury compared with PL/AG.
Ceftolozane-tazobactam showed excellent clinical and microbiological efficacy in treating GNB, especially P. aeruginosa-induced infections. The overall safety profile of ceftolozane-tazobactam was comparable to other antimicrobials, with no increased risk of CDI and obvious advantage over antibacterial agents with high nephrotoxicity.
未经授权:PubMed,Embase,和Cochrane数据库检索到2022年8月。纳入了评估成人GNB感染患者头孢特洛赞-他唑巴坦及其比较物的随机试验和非随机对照研究。
UNASSIGNED:共纳入13项研究,共4,167名患者。总的来说,接受头孢特洛赞-他唑巴坦的患者在临床治疗中具有显着的优势(优势比[OR],1.62;95%CI,1.05-2.51)和微生物根除(OR,1.43;95%CI,1.19-1.71),尤其是铜绿假单胞菌感染的患者。与多粘菌素/氨基糖苷类(PL/AG)或左氧氟沙星相比,头孢洛扎-他唑巴坦在临床成功或微生物根除方面具有显着优势。不良事件(AE)无显著差异,艰难梭菌感染(CDI),头孢特洛扎-他唑巴坦和比较者之间的死亡率。值得注意的是,头孢洛赞-他唑巴坦与PL/AG相比,急性肾损伤的风险明显降低。
未经评估:头孢洛扎-他唑巴坦在治疗GNB方面表现出优异的临床和微生物学疗效,尤其是铜绿假单胞菌引起的感染。头孢洛扎-他唑巴坦的总体安全性与其他抗菌药物相当,CDI的风险没有增加,与高肾毒性的抗菌药物相比具有明显优势。